當今全球面臨高齡化社會與護理人力短缺的雙重挑戰，醫療照護系統的負擔日益沉重。在此背景下，創新型醫療敷料的發展扮演著至關重要的角色，不僅有助於提升傷口照護的效率與品質，更可減少照護人力的依賴，對長照機構與醫療體系皆有實質助益。
奈米科技與人源外泌體的結合為創新型傷口敷料的開發帶來了巨大的潛力，特別是在加速傷口癒合、抗炎及組織再生方面。然而，這一技術的商業化應用面臨著嚴格的法規挑戰。本研究旨在分析當前全球主要市場（如美國、歐洲及中國）的法規環境，探討這類產品在各市場中的合規要求和商業化路徑。研究發現，雖然各地法規機構對於奈米技術和外泌體產品的審查標準不盡相同，但皆對產品的安全性、有效性及質量控制提出了高標準的要求。針對這一新興技術的商業化策略，企業需首先進行嚴格的臨床前和臨床試驗，確保產品符合醫療器材分類中的相關法規要求，並制定詳細的品質管理計劃，以確保生產過程中的一致性。此外，知識產權保護和市場教育也被確立為成功商業化的關鍵要素。最後，隨著技術和法規的不斷演進，持續監測法規更新與跨國法規合作將是企業保持競爭優勢的重要策略。本研究為相關企業在面對法規挑戰時提供了寶貴的參考與指導。

As the world faces the dual challenges of an aging population and a shortage of healthcare professionals, the burden on medical and caregiving systems continues to intensify. Against this backdrop, the development of innovative wound dressings plays a critical role—not only in enhancing the efficiency and quality of wound care, but also in reducing dependence on caregiving manpower. This offers tangible benefits to both long-term care facilities and healthcare systems.
The integration of nanotechnology and human-derived exosomes presents significant potential for the advancement of next-generation wound dressings, particularly in accelerating wound healing, reducing inflammation, and promoting tissue regeneration. However, the commercialization of this technology faces stringent regulatory hurdles. This study aims to analyze the current regulatory landscape in major global markets—namely the United States, Europe, and China—to explore the compliance requirements and commercialization pathways for such products.
Findings indicate that while regulatory standards for nanotechnology and exosome-based products vary across regions, all emphasize rigorous requirements for product safety, efficacy, and quality control. To successfully commercialize these emerging technologies, companies must first conduct comprehensive preclinical and clinical trials to ensure compliance with relevant medical device classifications. In addition, the establishment of robust quality management systems is essential to maintain consistency in manufacturing processes. Intellectual property protection and market education are also identified as critical success factors. Finally, in light of ongoing advancements in both technology and regulation, continuous monitoring of regulatory updates and engagement in international regulatory harmonization will be vital for maintaining competitive advantage. This study provides valuable insights and guidance for industry stakeholders navigating the complex regulatory environment surrounding the commercialization of such innovative medical technologies.

論文審定書 i
摘要 ii
Abstract iii
目錄 v
表目錄 vi
第一章 緒論 1
第一節 研究背景與動機 1
第二節 研究目的 2
第二章 產業現況 5
第一節 台灣醫療敷料產業現況與未來成長空間 5
第二節 國際醫療敷料產業現況與未來成長空間 7
第三章 文獻探討與分析 10
第一節 破壞式創新理論 10
第二節五力分析 13
第三節SWOT分析 14
第四節 賽局理論、納許均衡與產業競爭策略之應用 16
第五節 創新產品擴散理論與醫療敷料創新應用 19
第四章 研究結果 21
第一節 公司介紹與商業分析 21
第二節 創新型敷料在市場中的破壞式創新機會與挑戰 24
第三節 五力分析於醫療敷料產業之分析 26
第四節SWOT分析 27
第五節 賽局理論、納許均衡與醫療敷料產業競爭策略之應用 31
第六節 創新產品擴散理論與醫療敷料創新應用 34
第七節 核心能力盤點 35
第五章 結論與建議 38
參考文獻 39

一、 英文文獻
Liu, S., He, Y., Jiang, T., Zhang, Y., Li, Y., Wang, X., ... & Chen, H. (2024). Exosome-coated oxygen nanobubble-laden hydrogel augments chronic wound healing by resolving local hypoxia and inflammation. Nature Communications, 15(1), 1–15. https://doi.org/10.1038/s41467-024-47696-5
Zhang, Y., Bi, J., Huang, J., Li, Q., Chen, W., Xu, X., ... & Liu, T. (2023). Exosome-laden hydrogel wound dressing for point-of-care treatment of infected wounds. Bioengineering, 11(8), 804. https://doi.org/10.3390/bioengineering11080804
Zhang, J., Chen, Y., Luo, Y., Li, M., Fang, Q., & Wang, H. (2023). Extracellular vesicles in nanomedicine and regenerative medicine: Current trends and future perspectives. Nano Today, 54, 101880. https://doi.org/10.1016/j.nantod.2023.101880
Wang, C., Wang, M., Xu, T., Liu, H., Liu, Z., & Zhang, L. (2024). Nanomanaging chronic wounds with targeted exosomes. Advanced Drug Delivery Reviews, 200, 114627. https://doi.org/10.1016/j.addr.2023.114627
Wang, M., Han, X., Li, H., Zhang, Y., Wang, T., & Chen, Y. (2022). Exosomes derived from stem cells: Promising therapeutics for wound healing. Frontiers in Pharmacology, 13, 957771. https://doi.org/10.3389/fphar.2022.957771
Trinh, N. T. H., Phan, N. L. C., Le, T. T., Ngo, D. Q., Nguyen, H. T., Nguyen, Q. T., ... & Bui, A. V. (2021). Chitosan wound dressings incorporating exosomes derived from miR-126-3p-overexpressing SMSCs promote wound healing. Stem Cell Research & Therapy, 12, 736. https://doi.org/10.1186/s13287-021-02706-6
 
二、 中文文獻
王昕、陳湘婷（2021）。外泌體在傷口癒合與皮膚修復之研究進展。《中華醫學研究雜誌》，12(3)，45–50。
林孟潔、楊士弘（2023）。奈米材料在智慧醫療敷料中之應用探討。《生物醫學工程季刊》，27(2)，123–130。
張文豪、李佩蓉（2022）。結合人源外泌體之水凝膠敷料於燒燙傷癒合之研究。《台灣醫學》，26(4)，214–222。
余明哲（2023）。醫療器材產業創新與破壞式創新策略分析。《科技管理評論》，38(1)，77–90。